Holen Sie sich die Stockscreener-App
98.05
1.48%
-1.47
Handel nachbörslich:
98.99
0.94
+0.96%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Merck Co Inc Aktie (MRK) Neueste Nachrichten
Down 18% in 1 Day, Is Viking Therapeutics Stock in Trouble Due to Merck? - The Motley Fool
Merck - Contract Pharma
Merck-AstraZeneca breast cancer drug reduces risk of death by 28% in patients diagnosed early, clinical trial shows - AOL
Merck & Co., Inc. (NYSE:MRK) Trading Down 0.8%Time to Sell? - MarketBeat
Merck: LM-299 antibody agreement finalized - Marketscreener.com
BMO cuts rating on Merck and Biogen, on lack of near term catalyst - Investing.com
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
BMO Capital Markets Downgrades Merck & Co., Inc. (NYSE:MRK) to Market Perform - MarketBeat
Merck’s doravirine/islatravir combo yields positive results in Phase 3 HIV-1 trials - World Pharmaceutical Frontiers
Merck secures global rights to novel cancer therapy - Investing.com
Is Merck & Co. (MRK) a Cheap NYSE Stock to Invest in Now? - Insider Monkey
Merck & Co buoyed by Phase III results with HIV tablet - The Pharma Letter
Merck (NYSE:MRK) Has A Pretty Healthy Balance Sheet - Simply Wall St
Merck Closes Exclusive Global License Agreement for LM-299, An Investigational Anti-PD-1/VEGF Bispecific Antibody - Business Wire
Analyst recommendations: Fedex, Merck, Nike, Coinbase, Tesla... - Marketscreener.com
Merck stock downgraded by BMO amid Gardasil, Keytruda concerns - Investing.com
Merck & Co Inc (MRK) DCF Valuation: Is The Stock Undervalued? - The Acquirer's Multiple
Merck & Co. Inc. stock outperforms competitors on strong trading day - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Shares Up 0.5%What's Next? - MarketBeat
Merck's Investigational Two-Drug Regime For HIV Meets Primary Goal In Two Late-Stage Trials - Benzinga
Merck & Co (MRK) technical analysisMerck & Co (NYSE:MRK), Hansoh Pharmaceutical Gr (OTC:HNSPF) - Benzinga
Merck: encouraging phase III results in HIV - Marketscreener.com
Merck's HIV treatment meets main goal in two late-stage studies - Reuters
Merck Buys $50 Million of Personalis Stock - Marketscreener.com
Personalis Advances Business Strategy with Investment from Merck and Extends Collaboration with Moderna - Yahoo Finance
Merck shares reaffirm Market Perform rating on global in-licensing - Investing.com
Merck: Healthcare Pharma Giant: 3.2% Yield, 9.3% 5-Year Dividend Growth, Buy Time - Seeking Alpha
Merck Enters Obesity Space, Buys Rights to Hansoh's Oral GLP-1 Drug - Yahoo Finance
Merck’s RSV antibody could soon paddle into the rough waters of a crowded market - PharmaVoice
Merck's HIV-1 treatment meets efficacy in Phase 3 trials - Investing.com
Merck's HIV treatment meets main goal of two late-stage studies - Marketscreener.com
Merck stock slips after trial data for HIV drug (MRK:NYSE) - Seeking Alpha
Merck gets rights to Hansoh Pharma’s investigational diabetes drug - World Pharmaceutical Frontiers
Merck (MRK) Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir - StreetInsider.com
Merck Announces Topline Results from Pivotal Phase 3 Trials Evaluating Investigational, Once-Daily, Oral, Two-Drug, Single-Tablet Regimen of Doravirine/Islatravir (DOR/ISL) for the Treatment of Adults with Virologically Suppressed HIV-1 Infection - Marketscreener.com
Why Is Merck & Co., Inc. (MRK) Among the Best Dividend Stocks to Invest In? - Yahoo Finance
Merck snags Chinese obesity drug in nearly $2 billion deal - Fortune
Merck (MRK) Stock Moves -1.72%: What You Should Know - Yahoo Finance
Merck strikes a $2B GLP-1 deal with Hansoh - BioWorld Online
Deal Watch: Merck Decides Better Late Than Never In GLP-1 Deal With Hansoh - Citeline News & Insights
Merck & Co. Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Merck & Co., Inc. (NYSE:MRK) Trading Up 0.4%Still a Buy? - MarketBeat
Merck reaches weight-loss drug deal worth up to $2 billion with China-based Hansoh - Yahoo Finance
Merck & Co. taps Chinese biotech for entry into oral GLP-1 arena - FirstWord Pharma
Merck & Co buys in oral GLP-1 RA from China’s Hansoh - The Pharma Letter
Spotlight On: Merck enters the obesity game — four key takeaways - FirstWord Pharma
What's Going On With Viking Therapeutics Stock On Wednesday? - Yahoo Finance
Merck Acquires Potential Weight Loss Drug for $2 Billion - GuruFocus.com
Merck moves into obesity with deal for Hansoh’s GLP-1 pill - BioPharma Dive
Merck in global license agreement with Hansoh Pharma for weight-loss drug - ShareCast
Elon Musk, Netflix fined, Merck's GLP-1 deal: Market Minute - Yahoo Finance
Merck pens $2bn deal for obesity drug from China’s Hansoh - Proactive Investors USA
Merck signs up to $2 billion deal for oral weight-loss drug with China's Hansoh - Reuters.com
Merck-Hansoh deal for oral GLP-1 hurts obesity drug developers - Seeking Alpha
Merck stock holds Outperform rating on strategic move - Investing.com
Viking Plummets After Merck Inks A $2.01 Billion Obesity Deal — With Someone Else - Yahoo! Voices
Merck's BLA for RSV Antibody Clesrovimab Gets FDA Acceptance - Yahoo Finance
Merck to End Development of Two Cancer Candidates: Time to Sell? - Yahoo Finance
What's Going On With Merck Shares Wednesday? - Benzinga
Merck Joins Obesity Pill Race With $2B Hansoh Deal - BioSpace
Strong Fundamentals And Weight Loss Entry Make Merck (MRK) A Buy - Yahoo Finance
Merck & Co. signs license agreement for Hansoh Pharma GLP-1 receptor agonist - BioWorld Online
Merck & Co cuts TIGIT and LAG-3 programs - The Pharma Letter
0.35%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):